Clinical trials, among several critical purposes, are essential for the evaluation and approval of medication options for patients living with inflammatory bowel diseases. Despite this, only 6% of clinical trials are completed on time due to unfulfilled enrollment, often stemming to communication barriers between clinicians and patients.
Host Dr. Caren Heller, Chief Scientific Officer at the Crohn's & Colitis Foundation, sits down with Dr. William Sandborn, Professor of Medicine and Adjunct Professor of Surgery at the University of California-San Diego, about the many benefits that clinical trials can provide for IBD patients.
